Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
they're getting ready to re-open. Thank fook for that! Now lets play.
lot of people tied up in this one. So no matter what anyone says, there'll be a lot of movement in the sp when this opens up and it will.
going be a long day!
Comes with gambling. I'm down about 30k on a couple of shares which isn't that bad, considering I made a small fortune on others. The thing is, when companies like Tric continue to trade when suspended, there is always a chance that they may re-list (however small that maybe). If you think about it, they managed to list in the first place and we wouldn't of known anything about them before they did. On re-listing, that's when the fun really begins - a chance to claw back losses or to make some real money?!
find that a pattern is emerging with quite a few of the smaller Aim shares. Temp suspension do to not fulfilling certain requirements as set out in........ I'm assuming they jumped on to Aim at about the same time and are now suffering for not adhering to the rules. Some will get back in others will die.
are showing 35p also.
I also have a substantial holding in MHG and it looks like that is about to come out of suspension with an almighty boom! TRIC could also go the same way.
Nominated Adviser & Broker 020 7614 5900 Arden Partners plc chris.hardie@arden-partners.com Chris Hardie Kreab Gavin Anderson 020 7074 1800 Robert Speed rspeed@kreabgavinanderson.com Deborah Walter dwalter@kreabgavinanderson.com Notes for Editors Deltex Medical manufactures and markets the CardioQ-ODMO system. CardioQ-ODM changes the way doctors care for surgical patients allowing them to recover faster and leave hospital sooner and in better health than they otherwise would do. The performance of the system has been validated through independently conducted, randomised controlled clinical trials and is being translated into routine clinical practice in leading hospitals around the world. CardioQ-ODM comprises a monitor and a single patient disposable probe. The probe is placed into the oesophagus through either the mouth or nose and the tip positioned facing the adjacent descending aorta. A low frequency ultrasound signal, generated by the monitor, is bounced off the blood travelling down the aorta and the Doppler principle is used to determine the velocity of the blood flow, expressed in distance per cardiac cycle - 'Stroke Distance'. The monitor also calculates the amount of time that blood is flowing down the aorta as a proportion of a cardiac cycle - 'Flow Time'. The monitor uses a validated proprietary nomogram to extrapolate volumetric data (Stroke Volume, Cardiac Output etc) from the directly measured flow velocity. The nomogram utilises the patient's age weight and height, effectively to estimate the size of the aorta in which the velocity of the flow is being measured. Crucially this means that any reported relative change in Stroke Volume is absolutely identical to the relative change in the directly measured flow velocity variable of Stroke Distance. CardioQ-ODM immediately and reliably identifies even very small changes in the blood flow velocity allowing doctors to intevene earlier and on smaller changes than with any other approach. Intra-operative individualised Doppler guided fluid management entails insertion and focusing of the probe to obtain a baseline reading, giving a small (200 to 250 ml) fluid challenge directly into the vascular system and seeing if Stroke Volume (or Stroke Distance) increases by more than 10%. If the increase is more than 10%, repeat fluid boluses are administered until such time as the increase is less than 10%: after this no further fluid is given unless Stroke Volume falls by more than 10% - the process is designed to achieve and maintain the individual patient's optimal Stroke Volume. CardioQ-ODM is also used during surgery to guide administration of vaso-active agents such as inotropes. The CardioQ-ODM helps patients by enabling doctors to reduce the complications that arise from a medical condition that is common to almost all patients having surgery and many others in intensive care or
TIDMDEMG RNS Number : 8870D Deltex Medical Group PLC 30 March 2011 Deltex Medical Group plc Final NICE guidance recommends CardioQ-ODM(TM) 30 March 2011 - Deltex Medical Group plc ("Deltex Medical" or the "Company"), the global leader in oesophageal Doppler monitoring ("ODM"), announces that the National Institute for Health and Clinical Excellence ("NICE") has today published final guidance recommending the Company's CardioQ-ODM system. NICE issued preliminary guidance on Deltex Medical's CardioQ-ODM in October 2010. Following public consultation the breadth of NICE's recommendation has been increased to cover "patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring". In its guidance on implementation by the NHS, NICE estimates that its recommendation applies to 837,000 surgical patients each year in the NHS in England alone. Across the UK as a whole, using NICE's estimated average saving per patient of GBP1,100 per hospital stay, this represents a potential GBP1 billion annualised saving. NICE's guidance is at guidance.nice.org.uk/MTG3 and the final guidance states: "1.1 The case for adopting the CardioQ-ODM in the NHS, when used as described in 1.2, is supported by the evidence. There is a reduction in post-operative complications, use of central venous catheters and in-hospital stay (with no increase in the rate of re-admission or repeat surgery) compared with conventional clinical assessment with or without invasive cardiovascular monitoring. The cost saving per patient, when the CardioQ-ODM is used instead of a central venous catheter in the peri-operative period, is about GBP1100 based on a 7.5-day hospital stay. 1.2 The CardioQ-ODM should be considered for use in patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring." Ewan Phillips, Deltex Medical's Chief Executive, commented: "NICE's final guidance is a resounding endorsement for the CardioQ-ODM at a time when the NHS is charged with delivering GBP20 billion of efficiency savings over the next four years. Implementing this guidance in full would be a significant step towards the NHS delivering these savings while improving considerably the care given to those patients undergoing major and high risk surgery. "The NICE guidance follows on from the 'How to, Why to' guide published in 2010 by the NHS National Technology Adoption Centre setting out 'real world' lessons on how to implement effectively the CardioQ-ODM into routine practice in NHS hospitals." For further information, please contact:- Deltex Medical Group plc 01243 774 837 Nigel Keen, Chairman njk@deltexmedical.com Ewan Phillips, Chief Executive eap@deltexmedical.com Paul Mitchell, Finance Director pjm@delte
LONDON (Dow Jones)--Deltex Medical Group PLC (DEMG.LN), global oesophageal Doppler monitoring firm, said Wednesday the National Institute for Health and Clinical Excellence, or NICE, has published final guidance recommending the Company's CardioQ-ODM system. MAIN FACTS: -NICE issued preliminary guidance on Deltex Medical's CardioQ-ODM in October 2010. -Following public consultation the breadth of NICE's recommendation has been increased to cover "patients undergoing major or high-risk surgery or other surgical patients in whom a clinician would consider using invasive cardiovascular monitoring". -Shares at 0820 GMT up 8 pence, or 39%, at 28 pence valuing the company at GBP37 pence. -By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; ian.walker@dowjones.com
Thu, 24th Mar 2011 07:00 RNS Number : 5203D Biome Technologies PLC 24 March 2011 ? 24 March 2011 Biome Technologies plc ("Biome", "the Company" or "the Group") Preliminary Results Biome Technologies plc announces its Preliminary Results for the year ended 31 December 2010. Financial Highlights · Group revenue up 24% to £13.4m on a like-for-like basis*, ahead of market expectations · Loss from operations reduced to £1.9m (2009: loss £2.6m), ahead of market expectations · Loss before tax reduced to £2.3m (2009: loss £3.6m) · Cash utilised by operations reduced to £1.1m (2009: £2.3m) · Closing Group cash position £4.0m, following successful completion of equity fundraising in June 2010, raising £2.7m net of expenses to drive development of the Group * Reported Group revenue in 2009 of £17.9m included 100% consolidation of the Biotec JV - now only 50% consolidated; Group revenues reduced from £17.9m to £13.4m in 2010, reflecting the change in accounting treatment of Biotec described above Business Highlights · 16% growth in Bioplastics Division revenue on a like-for-like basis which includes: - 44% growth in revenue made by Biome Bioplastics, the wholly owned UK headquartered bioplastics business - 7% growth in Biotec's third party revenue, despite short term constraints in the supply chain · 81% growth in revenue in Stanelco RF Technologies delivering improved divisional profitability Paul Mines, Chief Executive, said: "The business emerges from 2010 in a robust position. The successful fundraising completed during the year has strengthened our balance sheet and sales continued to grow strongly in Biome Bioplastics and Stanelco RF Technologies through the period. We reduced the operating loss again, for the fourth consecutive year. We are pleased to find an increasing number of customers are choosing Biome's bioplastics for a variety of end uses and we are making significant progress with a number of innovative new materials" John Standen, Non-Executive Chairman, said: "In the first two months of 2011 the Group's results are well ahead of the same period in 2010 and ahead of the Board's expectations. This serves to illustrate the continuing growth prospects for our business in a fast expanding marketplace. We are well placed to continue delivering on our strategy through 2011 and the Board is confident in and encouraged by the outlook for the business."
I'm not going to get into an argument, but it's obvious that you haven't looked at the accounts, nor are you experienced in running a business. A poor attempt at deramping. Any company that manages to reduce it's losses is headed the right way, and no one could expect to turn x million profit from x million loss in a year! Absolutely ridiculous statement.
It's a real shame that there has been no posting this morning. BIOM is a company with good prospects and however you may look at the world today, Green issues come in and out of the media's eyes on a monthly basis. Fuelled by the antics of the EU, there will IMHO always be a need for green companies - more so now and in the future.